Search

Background: Despite the advent of vaccines against COVID‐19, there is considerable variation in the acceptance and hesitancy towards the vaccination program across different countries. The objective of this study was to ascertain the prevalence of hesitancy and acceptance regarding the use of the vaccine against the novel coronavirus, also known as COVID‐19, and to identify the factors that influence these attitudes. Materials and Methods: All the cross‐sectional studies were retrieved from the PubMed databases, the Web of Science ISI, Scopus, and the Cochrane Library. Papers published in English between 2 November 2019 and 23 May 2023 were subjected to further assessment based on their title, abstract, and main text, with a view to ensuring their relevance to the present study. Results: Following an exhaustive investigation, 59 studies were selected for screening in this systematic review. The most frequently employed method of data collection was the online survey. The study sample comprised 59.12% women and 40.88% men, with ages ranging from 16 to 78 years. The proportion of individuals accepting the vaccine ranged from 13% to 96%, while the proportion of those exhibiting hesitancy ranged from 0% to 57.5%. The primary reasons for accepting the COIVD‐19 vaccine were a heightened perception of risk associated with the virus and a general trust in the healthcare system. The most frequently cited reasons for vaccine hesitancy in the context of the ongoing pandemic include concerns about the potential dangers of the vaccines, the rapid pace of their development, the possibility of adverse effects (such as infertility or death), and the assumption that they have been designed to inject microchips. Discussion: A variety of socio‐demographic factors are implicated in determining the rate of vaccine acceptance. A number of socio‐demographic factors have been identified as influencing vaccine acceptance. These include high income, male gender, older age, marriage, the presence of older children who have been vaccinated and do not have chronic diseases, high education, and health insurance coverage. Conclusion: Eliminating vaccine hesitancy or increasing vaccine acceptance is a crucial factor that should be addressed through various means and in collaboration with regulatory and healthcare organizations. [ABSTRACT FROM AUTHOR]

Background: Disinfectants and antiseptics inhibit the dissemination of pathogenic organisms in hospitals but often cause disinfectant-resistant microorganisms, an important factor for nosocomial infection. This study aimed to evaluate the correlation between qacΔE efflux pump gene and its resistance to disinfectants among Escherichia coli clinical isolates. Methods: A total of 97 E. coli isolates were isolated from patients with urinary tract infections. The minimum inhibition concentration (MIC) value of chlorhexidine and benzalkonium chloride was determined using broth microdilution method. Effect of efflux pumps was assessed by MIC test in the presence of phenylalanine-arginine β-naphthylamide (PAβN), and then the qacΔE efflux pump gene was detected using polymerase chain reaction (PCR). Result: Of the isolates, 85.6% and 61.9% were resistant to chlorhexidine and benzalkonium chloride, respectively. Following the treatment of isolates with the efflux pump's inhibitor, PAβN, the MIC value of chlorhexidine and benzalkonium chloride decreased in 75.2% and 57.7% of the isolates, respectively. A significant correlation was found between PAβN treatment and the change in the resistant strains to susceptible strains (p = 0.021). The qacΔE gene was detected in 84.5% (n = 82) of the isolates, and the presence of the gene amongst disinfectant-resistant strains was also significant (p < 0.001). Conclusions: It is suggested to conduct other studies on other efflux pumps, as well as to periodically monitor the resistance to disinfectants. Substances inhibiting efflux pumps and neutral compounds are effective in the reduction of resistance to disinfectants. New disinfectants and drugs should be designed. [ABSTRACT FROM AUTHOR]

Background and Aim: Pseudomonas aeruginosa is an important ubiquitous and especially common pathogen in the hospital. Exotoxin A encoded by exoA gene has a role in the pathogenesis of this bacterium. Today, probiotics are widely used in the treatment and prevention of diseases. The present study aimed to study the Saccharomyces cerevisiae S3 effect on the expression of exoA gene. Materials and Methods: Saccharomyces cerevisiae S3 supernatant and lysate were prepared. Subminimum inhibitory concentrations (sub-MIC) of extracts were used against P. aeruginosa PAO1. The level of exoA expression was measured with Real-time PCR method. Results: Lysate extract reduced toxin gene expression, but unlike lysate, supernatant had an increasing effect on gene expression. Conclusion: We demonstrated that S. cerevisiae S3 inhibited Exotoxin A virulence factor of P. aeruginosa. We suggest doing more experiments on the effect of S. cerevisiae on other virulence factors of P. aeruginosa and pathogens. [ABSTRACT FROM AUTHOR]

BACKGROUND: COVID-19 is the last global threat which WHO confirmed it as a pandemic on March 11, 2020. In the Middle East, Iran was the first country where the SARS-Cov-2 was detected. The epidemiological and economic challenges of Iran make this country a particularly relevant subject of study. In the current study, we aimed to evaluate the clinical, radiological and laboratory findings in hospitalized COVID-19 confirmed cases in Ilam province, western of Iran. METHODS: Overall, 2204 hospitalized RT-PCR confirmed patients with COVID-19 were considered in this study. Electronic medical records, including clinical symptoms, radiological images, laboratory findings, and the comorbidities of patients with COVID-19 were collected and analyzed. In addition, the medication regimens used in these patients were evaluated. The patients were classified in discharged and died groups according to their outcomes. Then, clinical, radiological and laboratory findings as well as treatment regimens and underlying diseases were compared in these two groups. RESULTS: Among the patients, 1209 (54.85%) were male and 995 (45.14%) were female. Pneumonia, dyspnea and cough, were the most common clinical data in both discharged and died groups. Among the comorbidities, COPD, and cancer were significantly more common in the dead patients than in the living. The results of laboratory tests showed that blood creatinine, BUN, ESR, Na+, WBC, and neutrophil count have increased in deceased group compared to the survivors. However, the lymphocyte count decreased in deceased patients. The evaluation of radiographs demonstrated that there were significant correlations between bilateral pneumonia, ground glass opacity, bilateral patchy shadowing, and pleural effusion with death. CONCLUSION: The current investigation indicated the special profile of COVID-19 in west of Iran. Discharged and dead patients with COVID-19 had distinct clinical, radiological and laboratory features, which were separated by principal component analysis. Identifying these characteristics of the disease would translate into the implementation of practical measures to improve results. [ABSTRACT FROM AUTHOR]

This study aims to investigate the development of secondary bacterial infection and risk factors associated with it in critical COVID-19 patients, and to identify the most common pathogen groups in them. All the cohort studies were retrieved from Scopus, Google Scholar, Web of Science, and MEDLINE from the inception of COVID-19 to 2022 for the following keywords: ' Klebsiella " AND "COVID-19". The most common comorbidities among the patients with COVID-19 were respiratory disease (33.62%), obesity (28.99%), and heart disease or cardiovascular disease (16.31%). We report 42.91% rate of Klebsiella spp co-infection in ICU admission patients, mostly related to K. pneumonia (26.81%), K. aerogenes (9.4%), and K. oxytoca (6.7%). The overall incidence of bacterial infection in hospitalized COVID-19 patients is estimated at 15.5% and in 32.5% of cases of co-infection patients deceased. The threat of carbapenem-resistant K. pneumoniae infections in patients with COVID-19 is imminent, therefore rational antibiotic therapy based on antibiotic sensitivity test should be implemented. [Display omitted] [ABSTRACT FROM AUTHOR]

• Tigecycline used in the treatment of methicillin-resistant Staphylococcus aureus infections. • This study indicates very little resistance to tigecycline in methicillin-resistant Staphylococcus aureus infections. • There was significantly high heterogeneity among the studies. • USA had heterogeneity among the studies done among countries. Tigecycline (TG) is one of the newest antimicrobial drugs used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. The TG Resistance Evaluation and Monitoring Test (T.E.S.T.) is a global surveillance study aimed at monitoring bacterial resistance to TG in MRSA. This study will provide comprehensive data on the activity of TG against MRSA strains across the world by 2022. An electronic search was conducted for articles published during 1997 to 2022 in Pubmed/Medline (n = 361), Scopus (n = 1735) and Web of science (n = 439) for the following keywords: ((Tygacil [Title/Abstract]) OR (Tigecycline [Title/Abstract])) AND (((Staphylococcus aureus [Title/Abstract]) OR (Methicillin resistant Staphylococcus aureus [Title/Abstract])) OR (MRSA [Title/Abstract])). The titles and abstracts of 2535 articles were screened and 48 publications that fulfilled the inclusion criteria were included. From all studies, 35 studies had a cross-sectional design, 11 studies were cohort and 2 studies were case control. Blood and respiratory tract were the main specimen source in MRSA. Meta-analysis showed the proportion of TG resistance is more than 0.004. The region (countries, continent), study type and detection method were examined as the contributing factors of heterogeneity among the studies. Microbial resistance to this antibiotic has been reported to be low, but this does not mean that it can be used widely and without supervision, but the resistance caused by it in MRSA and other pathogens should be carefully and regularly evaluated. [ABSTRACT FROM AUTHOR]

Aim: Both immunocompetent and healthy individuals can become life-threateningly ill when exposed to the hypervirulent (hvKp) strains of Klebsiella pneumoniae (Kp). The main objectives of this study were to evaluate the presence of ampC-lactamase genes, biofilm formation, and antibiotic resistance in clinical strains of hvKp and cKp (classical K. pneumoniae)., Materials and Methods: Kp strains were collected from patients referred to Shahidzadeh Hospital in Behbahan City, Khuzestan Province, Iran. Several techniques were used to identify hvKp. The hypermucoviscosity phenotype was determined using the string test. Isolates that developed dark colonies on tellurite agar were assumed to be hvKp strains. If any of the iucA, iutA, or peg-344 genes were detected, the isolates were classified as hvKp. Phenotypic and genotypic detection of AmpC β-lactamases of hvKp strains was performed by the combined disk method and polymerase chain reaction, respectively. In addition, crystal violet staining was used to determine the biofilm formation of these isolates., Results: For this study, 76 non-duplicative isolates of Kp were collected. Overall, 22 (28.94%) strains had positive string test results, and 31 (40.78%) isolates were grown in tellurite-containing medium. The genes iucA and iutA or peg-344 were found in 23.68% of all Kp strains and in 50% of tellurite-resistant isolates, respectively. The most effective antibiotics against hvKp isolates were tetracycline (85.52%) and chloramphenicol (63.15%). Using the cefoxitin disc diffusion method, we observed that 56.57% (43/76) of the strains were AmpC producer. A total of 30.26% (n = 23/76) of the isolates tested positive for at least one ampC gene, including blaDHA (52.63%, n = 40), blaCIT (40.78%, n = 31), blaACC (19.76%, n = 15), blaMOX (25%, n = 19), and blaFOX (43.42%, n = 33). Biofilm formation analysis revealed that most hvKp isolates were weak (n = 6, 40%) and moderate (n = 5, 33.33%) biofilm producers., Conclusion: Healthcare practitioners should consider the possibility of the existence and acquisition of hvKp everywhere. The exact mechanisms of bacterial acquisition are also unknown, and it is unclear whether the occurrence of infections is related to healthcare or not. Thus, there are still many questions about hvKp that need to be investigated., (© The Author(s) 2023. Published by Oxford University Press on behalf of Applied Microbiology International.)